KLRK1 and acute myeloid leukemia: These cells strongly contribute to drug resistance [155,156] and are characterized by poor expression of NKG2D ligands [157], which makes them distinctively less vulnerable as compared with bulk AML cells to the NKG2D-dependent effector functions.